Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Svarvar, P.
Right arrow Articles by Aly, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svarvar, P.
Right arrow Articles by Aly, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 43-50
© 2000 British Society for Rheumatology

SUPPLEMENT

Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway

P. Svarvar and A. Aly1

Outcomes Research, Medical Department, Pfizer AB
1 Stockholms Sjukhem, Stockholm, Sweden

Correspondence to: Correspondence to: P. Svarvar, Outcomes Research Manager, Nordic Coordinator, Pfizer Inc, Sweden.

Abstract

A Norwegian customization of the Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to predict the economic and health impact of the introduction of celecoxib in Norway. The model predicts that use of celecoxib can be expected to result in a reduction in gastrointestinal events with concomitant annual net savings of at least Norwegian krone (NOK) 580 per osteoarthritis (OA) patient and NOK 514 per rheumatoid arthritis (RA) patient. In a cost-effectiveness analysis, celecoxib demonstrated economic dominance (i.e. improved health at reduced cost) compared with the currently available alternatives. In sensitivity analyses, the results of this model have been shown to be relatively robust, with celecoxib demonstrating economic dominance or favourable cost-effectiveness ratios in all analyses. Based on these data, it can be concluded that the introduction of celecoxib into the Norwegian non-steroidal anti-inflammatory drug market, and its use as a first-line agent, will provide societal benefits by improving health care at reduced cost in patients with OA and RA.

KEY WORDS: Pharmacoeconomics, Health outcomes, NSAIDs, Celecoxib, Norway, Cost-effectiveness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
J J Haringman, M C Kraan, T J M Smeets, K H Zwinderman, and P P Tak
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis
Ann Rheum Dis, August 1, 2003; 62(8): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
T J M Smeets, E C Barg, M C Kraan, M D Smith, F C Breedveld, and P P Tak
Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis
Ann Rheum Dis, July 1, 2003; 62(7): 635 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M D Smith, E Barg, H Weedon, V Papengelis, T Smeets, P P Tak, M Kraan, M Coleman, and M J Ahern
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints
Ann Rheum Dis, April 1, 2003; 62(4): 303 - 307.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.